FUNDAMENTALS · Fundamentals · TW Healthcare

Bora Pharmaceuticals (6472) Fundamentals 2026 — P/E 32.9x, Revenue Analysis | SniperIQ

Bora Pharmaceuticals (6472) is a TW-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of NT$53.9B, trading at NT$423.00 on the TAI. This SniperIQ fundamentals page covers Bora Pharmaceuticals's valuation (P/E 32.9x, P/B 3.7x), profitability (net margin 8.7%), revenue (NT

9.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT$53.9B
P/E (TTM)32.9x
Net Margin8.7%
Revenue (FY25)NT
9.0B

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Bora Pharmaceuticals's market cap?

Bora Pharmaceuticals (6472) has a market capitalization of approximately NT$53.9B, trading at NT$423.00 on the TAI. Market cap moves with the live share price.

What is Bora Pharmaceuticals's P/E ratio?

Bora Pharmaceuticals's trailing twelve-month P/E ratio is 32.9x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Bora Pharmaceuticals?

Bora Pharmaceuticals runs a net profit margin of 8.7%, a gross margin of 39.4%, and an operating margin of 16.3%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Bora Pharmaceuticals generate?

Bora Pharmaceuticals reported revenue of NT

9.0B for fiscal year 2025, with net income of NT
.0B and earnings per share (EPS) of 23.9. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Bora Pharmaceuticals pay a dividend?

Bora Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Bora Pharmaceuticals financially healthy?

Bora Pharmaceuticals carries a debt-to-equity ratio of 1.20x and a current ratio of 1.38x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Bora Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Bora Pharmaceuticals (6472) the key facts are: market cap NT$53.9B, P/E 32.9x, revenue NT

9.0B, 52-week range 330.5-795. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Bora Pharmaceuticals's full fundamentals live

Get Bora Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.